

TENDER NO. BMSIC/DRUGS/18-12

Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name: M/s Alpha Laboratories Ltd. Total Number of Pages Submitted in bid documents

Sl. No	SBD clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List	Document/ fees submission status (Yes/ No)	Page number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3. (a)	Tender Fee (Non –Refundable) of Rs 10,000/- in form of Demand Draft drawn in Favor of “Managing Director, Bihar Medical Services and Infrastructure Corporation Limited” payable at Patna. This fee is payable only once for one tender irrespective of items contained therein.	Yes	133	Yes	
2	3.(b)	Bidder are required to submit Earnest Money Deposit in the form of Demand Draft / Bank Guarantee drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna as follows:- Upto 5 drugs- Rs1,00,000/- (One Lakh only), for 6 to 10 drugs- Rs 2,00,000/- (Two Lakh only), for 11 to 20 drugs- Rs 3,00,000/- (Three Lakh only) and for More than 20 drugs Rs 5,00,000/- (Five Lakh only)	Yes	127-132	Yes	
3	3.(c)	Documentary evidence of the constitution of the company/ firm/ Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	Yes	48-90	Yes	
4	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	40-41	Yes	
5	3.(e)	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As per Clause 3(e) of the NIT. Format to be used.	Yes	91	Yes	
6	3.(f)	Copies of the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 Crores for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). Self-attested copies are to be submitted.	Yes	139-145	Yes	

Chandra 16-12-18
82
19/01/19

19

7	3.(m)	Copy of Income Tax Return for any three of last four Consecutive Assessment years should be submitted (self-attested).	Yes	134-136	Yes	
8	3.(p)	Copy of PAN Card of the bidder company should be submitted (self-attested).	Yes	137	Yes	
9	3.(q)	Copy of certificate of valid Sales Tax/VAT and GST registration of the bidder company should be submitted (self-attested).	Yes	138	Yes	

Chandelan
 14/07/2015
 19/07/15



TENDER NO. BMSIC/DRUGS/18-12

Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name M/s Alpa Laboratories Ltd. Total Number of Pages Submitted in bid documents- 145						
Sl. No	SBD Clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List	Document/ fees submission status (Yes/ No)	Page Number as numbered by BMSICL	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	YES	40	YES	
2	3.(e)	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As per Clause 3(e) of the NIT. Format to be used.	YES	41 & 91	YES	
3		Minimum three years old valid Manufacturing License of the product quoted with latest license renewal certificate.	YES	94-98	YES	
4		Approved product list as per the license issued for quoted drugs for minimum three years.	YES	99-104	YES	
5		Manufacturing License along with approved product list must be valid till the last date of the submission of tender.	YES	94-104	YES	
6		In Case of those drugs which are notified first time in IP 2014 then Manufacturing and Marketing license should be in any official compendium (USP/BP/IP) along with current valid License in IP in continuation.	-	-	-	

18/01/19
18/01/19

U. Pradeep
18.01.2019

7	3.(f)	Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation).	YES	106-110	YES	
8		If permission in Form 46 (For manufacturers) / Form 45 (For Importers) from DCGI has been obtained, then the 3 years manufacturing/ Import & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable.	-	-	-	
9		For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCGI (I) shall be required for all new regulated products to this effect.	-	-	-	
10		FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable	-	-	-	
		NOTE: Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	-	-	-	
11	3.(g)	In case of Importer, the bidder (importer) firm must have minimum three years old valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	-	-	-	

18/10/19
 18/10/19
 18/10/19
 18/10/19

12	3.(h)	Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. Self-attested copies are to be submitted.	YES	106-110	YES	
13	3.(i)	Non Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted. It should be not more than one year old. Self-attested copies are to be submitted. For Surgicals In case of Non-Drug item "the bidder shall submit an affidavit on Non-Judicial stamp paper stating that the quoted product is not covered under Drugs & Cosmetics Act."	YES	111-112	YES	
14	3.(j)	WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule-M/COPP Certificate of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department. The GMP certificate must not be older than one year from the last date of submission of tender. Self-attested copies are to be submitted.	YES	113-122	YES	

18/11/19
 18/11/19
 18/11/19
 18/11/19

15	3.(k)	Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section. Self-attested copies are to be submitted. In case of Importer An affidavit (With Stamp) sworn before first class magistrate/Notary stating the batch production capacity of the firm and also that said production(Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/Evidence of import in items of said product with quantity details.	YES	123	YES	
16	3.(n)	The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL as per Annexure-II.	YES	125-126	YES	
17	3.(o)	List of item quoted in prescribed format as per Annexure-III duly signed.	YES	92	YES	
18	5.(k)	An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure-IV.	YES	139	YES	
19	5.(l)	Filled check list as per given Annexure-VI to be submitted at the time of uploading the bid.	YES	37-39	YES	
20	7.(c)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.	-	-	-	
21	10.(c)	If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.	-	-	-	

18/01/19
 18/01/19
 18/01/19
 18/01/19

22	2 (d)	A Notarized affidavit on a Rs 100/- Non-Judicial Stamp Paper representing that the offered price is the lowest price as compared to the Rates provided to their respective Distributors/ Dealers/ Wholesalers/ Carrying and Forwarding Agents/ Authorized depot sales point in the State of Bihar.	YES	47	YES	
----	-------	--	-----	----	-----	--

गणेश शर्मा
18/01/19

18/01/19

18.01.2019

TENDER NO. BMSIC/DRUGS/18-12

Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company name: M/s Alpha Laboratories Ltd.

Total number of pages submitted in bid documents: 145

Sheet to be used for verification of product approval and market standing

SL. No	NIT SL. No	Name of the Quoted Drug		Pharmacopoeial Specification/ Strength		Pack Size		Dosage Form		Approval Details			Last 3yrs market standing certificate / New Drug
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	First Approval	Approved Upto	Approved in Brand /Generic Name	
1	1	LIGNOCAINE HYDROCHLORIDE INJECTION	LIGNOCAINE INJECTION IP 2 %	2%W/V	EACH ML CONTAINS: LIGNOCAINE HYDROCHLORIDE IP 20 MG SODIUM CHLORIDE IP 6.0 MG METHYL PARABEN IP 1.0 MG WATER FOR INJECTION IP Q.S.	30 ml vial	Not Mentioned	Injection	Injection	01.01.2013	31.12.2022	Brand	YES
2	2	TRAMADOL HYDROCHLORIDE INJECTION	TRAMADOL INJECTION	50 mg/ml	EACH ML CONTAINS:TRAMADOL HYDROCHLORIDE 50 mg EQ. TO TRAMADOL BASE 44.09 MG	2 ml Ampoule	Not Mentioned	Injection	Injection	01.01.2013	31.12.2022	Brand	YES
3	6	CEFOTAXIME SODIUM INJECTION	CEFOTAXIME SODIUM INJECTION IP	500 mg	Each Vial contains: CEFOTAXIME SODIUM IP Eq. to Cefotaxime 500 mg	Vial	Not Mentioned	Injection	Injection	01.01.2013	31.12.2022	Brand	YES
4	8	MEROPENEM INJECTION	MEROPENEM INJECTION IP 1 GM	1000 mg	EACH VIAL CONTAINS: STERILE MEROPENEM IP (AS TRIHYDRATE) EQ. TO MEROPENAM ANHYDROUS 1000 MG (ALSO CONTAINS 90.2 MG OF SODIUM AS SODIUM CARBONATE)	Vial	Not Mentioned	Injection	Injection	01.01.2013	31.12.2022	Generic	YES

gm 15/3/19

19/01/19

gm 15/3/19

gm 15/3/19

PINE LATE ION IP	600µg/ml	EACH ML CONTAINS: ATROPINE SULPHATE IP 0.6 mg WATER FOR INJECTION IP qs	Ampoule	Not Mentioned	Injection	Injection	01.01.2013	31.12.2022	Brand	YES
RTISONE UM TE FOR ION IP	100 mg	EACH VIAL CONTAINS: HYDROCORTISONE SODIUM SUCCINATE(BUFFERED) EQUIVALENT TO HYDROCORTISONE 100 MG	20 ml Vial	Not Mentioned	Injection	Injection	01.01.2013	31.12.2022	Brand	YES

gmbh BMT 21/11/19

08/10/19

*Not mentioned
18.01.2019*

TENDER NO. BMSIC/DRUGS/18- 12

Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids

Company name: M/s Alpa Laboratories Ltd. Total number of pages submitted in bid documents: 145

Sheet for verification of licence details

Sl. No	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)	
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To	From	To
1	1	LIGNOCAINE HYDROCHLORIDE INJECTION	28	28-02-99	-	-	18.03.99	31.12.2022	13.07.2017	12.07.2019
2	2	TRAMADOL HYDROCHLORIDE INJECTION	28	28-02-99	-	-	18.03.99	31.12.2022	13.07.2017	12.07.2019
3	6	CEFOTAXIME SODIUM INJECTION	28	28-02-99	-	-	18.03.99	31.12.2022	13.07.2017	12.07.2019
4	8	MEROPENEM INJECTION	28	28-02-99	-	-	18.03.99	31.12.2022	13.07.2017	12.07.2019
5	23	ATROPINE INJECTION	28	28-02-99	-	-	18.03.99	31.12.2022	13.07.2017	12.07.2019
6	24	HYDROCORTISONE SODIUM SUCCINATE INJECTION	28	28-02-99	-	-	18.03.99	31.12.2022	13.07.2017	12.07.2019

Note:- Assisted in technical evaluation the basis of document provided by BMSICL checklist II, III, & IV. Provided checklist complied with due diligence and care. Inspite, some in advertent discrepancies could have been crept in humble request to all concern to bring to the notice indue time if any discrepancies are observed for rectification.

gmm 18.03.19 MTHW
18/01/19

Uchawale
18.01.2019

18/01/19